Riskpilot← Back to searchSign inGet full accessPephexia Therapeutics ApS
APSActiveCVR 41319208Nordre Fasanvej 215, 4.Research and experimental development on natural sciences and engineering · NACE 7210Est. 20205 employeeswww.pephexia.com
Revenue 2024
DKK -2,1M
-35% vs 2023
EBITDA margin
278.2%
+4% vs 2023
Equity ratio
-259.7%
Financial strength
Net profit 2024
DKK -5,3M
+2% vs 2023
| Revenue | DKK -2,1M | -35% |
| EBITDA | DKK -5,8M | +4% |
| Net profit | DKK -5,3M | +2% |
| Total assets | DKK 5,9M | +12% |
| Equity | DKK -15,3M | -22% |
| Employees | 5 | — |
Legal name
Pephexia Therapeutics ApS
CVR number
41319208
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
24. april 2020
Share capital
DKK 71.654
Employees
5 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en direktør i forening med et bestyrelsesmedlem.
Company purpose
Virksomhedens formål er forskning og udvikling af lægemidler samt anden dermed beslægtet virksomhed efter direktionens skøn.
Address
Nordre Fasanvej 215, 4.
Phone
+4550910969
Email
kfo@pephexia.com
Website
www.pephexia.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -146 | 626 | -5.266 | -3.212 | -2.085 |
| Staff expenses | -0 | -861 | -2.598 | -2.801 | -3.715 |
| EBITDA | -146 | -5.599 | -7.864 | -6.013 | -5.801 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -146 | -5.599 | -7.864 | -6.013 | -5.801 |
| Net financials | -5 | -114 | -684 | -958 | -1.020 |
| Profit before tax | -152 | -5.713 | -8.548 | -6.972 | -6.821 |
| Tax | -22 | -1.181 | -1.871 | -1.532 | -1.500 |
| Net profit | -130 | -4.532 | -6.677 | -5.440 | -5.321 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 932 | 4.812 | 9.746 | 5.251 | 5.894 |
| Equity | 795 | -2.652 | -7.146 | -12.586 | -15.307 |
| Long-term debt | 0 | 7.090 | 12.462 | 16.672 | 20.186 |
| Short-term debt | 106 | 375 | 4.431 | 1.165 | 1.014 |
| Total debt | 106 | 7.464 | 16.893 | 17.837 | 21.200 |
EBITDA margin
-580090700.0%
This company
15.8%
Market median
-3671460227% vs market
20202024
Equity ratio
-259.7%
This company
38.2%
Market median
-780% vs market
20202024
Return on equity
-532087000.0%
This company
18.4%
Market median
-2891777274% vs market
20202024
Net profit margin
-532087000.0%
This company
8.1%
Market median
-6568975409% vs market
20202024
Asset turnover
-0.35×
This company
1.12×
Market median
-131% vs market
20202024
Debt / equity
1.39×
This company
0.62×
Market median
-124% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-04-24 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KF Management | Management | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Fogtmann Fosgerau Holding ApS | Company | 50.0% | 50.0% | 2022 |
| Individual | 5.0% | 5.0% | 2020 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Fogtmann Fosgerau Holding ApS
Pephexia Therapeutics ApS Board members of Pephexia Therapeutics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Keld Fogtmann Fosgerau | Management | 0 companies |
| Stefan Dietmar Anker | Board of Directors | 0 companies |
| Mats Peter Blom | Board of Directors | 0 companies |
| Yann Albert André Colardelle | Board of Directors | 0 companies |
| Anders Mørkeberg Hinsby | Chairman | 0 companies |